 |
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.
Breaking News:
| September 9, 2010 |
|
Bachem and Atheris collaborate on Melusine® venom peptide libraries for lead discovery
Bachem today announced that the company concluded an agreement with Atheris Laboratories to market their Melusine® libraries, consisting of natural products isolated from animal venoms. |
| - |
|
 morePressemitteilungPress Release
|
| August 20, 2010 |
|
Difficult start to first half-year of 2010 for the Bachem Group
Positive sales trend thanks to acquisition of projects and recovery of demand
In the first half of 2010, sales of the Bachem Group fell to 73.9 million CHF as a result of the difficult market conditions. |
| - |
|
Press ReleaseHalf-Year ReportPressemitteilungHalbjahresbericht |
|
July 28, 2010 |
|
Save 50% on selected Amino Acid Derivatives and Loaded Resins for Fmoc- and Boc-SPPS
Check out the complete list of heavily discounted products. |
|
special offers |
To view all breaking news, go to the archive
| |
